Article on a study where the CODOX-M/IVAC therapy regimen was modified for HIV Burkitt’s patients to reduce toxcity. Researchers added rituximab, reduced and/or rescheduled cyclophosphamide and methotrexate, capped vincristine, and used combination intrathecal chemotherapy.
Home / Resource Library / AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma